Is it possible to predict the long-term response to venlafaxine with the use of biological markers and psychophysiological methods?

Journal of Affective Disorders

Volumn 99, Issue 1-3, 2007, Pages 155-163

  Fountoulakis, K N ^a   Iacovides, A ^a   Karamouzis, M ^a   Gerasimou, G ^a   Grammatikos, Ph ^a   Fotiou, F ^a   Kaprinis, G ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Biological markers; Prognosis; Psychopharmacology; Psychophysiology; Venlafaxine

Indexed keywords

BIOLOGICAL MARKER; PROLACTIN; VENLAFAXINE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BRAIN BLOOD FLOW; CHI SQUARE TEST; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DEXAMETHASONE SUPPRESSION TEST; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ELECTROOCULOGRAM; EVOKED VISUAL RESPONSE; FEMALE; FENFLURAMINE CHALLENGE TEST; FOLLOW UP; GLOBUS PALLIDUS; HUMAN; LONG TERM CARE; MAJOR DEPRESSION; MALE; NEUROIMAGING; PATTERN REVERSAL VISUAL EVOKED POTENTIAL; PREDICTION; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT DURATION;

ADULT; ANTIDEPRESSIVE AGENTS; BRAIN; CHRONIC DISEASE; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DEXAMETHASONE; DEXFENFLURAMINE; DOMINANCE, CEREBRAL; ELECTROOCULOGRAPHY; ELECTRORETINOGRAPHY; EVOKED POTENTIALS, VISUAL; FEMALE; FOLLOW-UP STUDIES; GLOBUS PALLIDUS; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PROGNOSIS; PROLACTIN; RECURRENCE; REGIONAL BLOOD FLOW; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 33847052082     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2006.09.008     Document Type: Article

References (53)

1. Ad Sitsen J., and Montgomery S. In: Den Boer J., and Ad Sitsen J. (Eds). The Pharmacological Treatment of Depression and its Problems (1994) 349-377
2. Arden G., and Kelsey J. Changes produced by light in the standing potential of the human eye. Journal of Physiology (1962) 189-202
3. Arden G., Barrada A., and Kelsey J. New clinical test of retinal function based upon the standing potential of the eye. British Journal of Ophthalmology (1962) 449-467
4. Baron B., Ogden A., and Siegel B. Rapid down-regulation of beta-adrenoreceptors by Co-administration of desipramine and fluoxetine. European Journal of Pharmacology 154 (1988) 125-134
5. Baumann B., Danos P., Krell D., Diekmann S., Leschinger A., Stauch R., et al. Reduced volume of limbic system-affiliated basal ganglia in mood disorders: preliminary data from a postmortem study. Journal of Neuropsychiatry and Clinical Neurosciences 11 (1999) 71-78
6. Bench C., and Friston K. Regional cerebral blood flow in depression measured by PET: the relationship with clinical dimensions. Psychological Medicine 23 (1993) 579-590
7. Buchsbaum M., Wu J., and DeLisi L. Frontal cortex and basal ganglia metabolic rates assessed by positron emission tomography with [18F]2-deoxyglucose in affective illness. Journal of Affective Disorders 10 (1986) 137-152
8. Carroll B., Martin F., and Davies B. Resistance of suppression by dexamethasone of plasma 11-OHCS levels in severe depressive illness. British Medical Journal 3 (1968) 285-287
9. Chiappa K. Evoked Potentials in Clinical Medicine (1990), Raven Press, New York
10. Clerc G.E., Ruimy P., and Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The venlafaxine French inpatient study group. International Clinical Psychopharmacology 9 (1994) 139-143
11. Conca A., Fritzsche H., Peschina W., Konig P., Swoboda E., Wiederin H., and Haas C. Preliminary findings of simultaneous 18F-FDG and 99mTc-HMPAO SPECT in patients with depressive disorders at rest: differential correlates with ratings of anxiety. Psychiatry Research 98 (2000) 43-54
12. Di Renzo G., and Amoroso S. Pharmacological characterization of serotonin receptors involved in the control of prolactin secretion. European Journal of Pharmacology 162 (1989) 371-373
13. Evans D., and Golden R. The dexamethasone suppression test: a review. In: Nemeroff C., and Loosen P. (Eds). Handbook of Clinical Psychoneuroendocrinology (1987), John Wiley and Sons, New York 313-335
14. Fessler R., Deyo S., Meltzer H., and Miller R. Evidence that the medial and dorsal raphe nuclei mediate serotonergically-induced increases in prolactin release from the pituitary. Brain Research 299 (1984) 231-237
15. Fotiou F., Fountoulakis K.N., Iacovides A., and Kaprinis G. Pattern-reversed visual evoked potentials in subtypes of major depression. Psychiatry Research 118 (2003) 259-271
16. Fountoulakis K.N., Karamouzis M., Iacovides A., Nimatoudis J., Diakogiannis J., Kaprinis G., et al. Morning and evening plasma melatonin and dexamethasone suppression test in patients with nonseasonal major depressive disorder from northern Greece (latitude 40-41.5 degrees). Neuropsychobiology 44 (2001) 113-117
17. Fountoulakis K., Iacovides A., Fotiou F., Karamouzis M., Demetriadou A., and Kaprinis G. Relationship among Dexamethasone Suppression Test, personality disorders and stressful life events in clinical subtypes of major depression: an exploratory study. Annual General Hospital Psychiatry 3 (2004) 15
18. Fountoulakis K., Kaprinis S., Iacovides A., Fotiou F., and Kaprinis G. Biological markers and psychophysiological methods as long term response predictors to fluoxetine treatment. Journal of Affective Disorders 80 (2004) 291-292
19. Fountoulakis K.N., Iacovides A., Fotiou F., Nimatoudis J., Bascialla F., Ioannidou C., et al. Neurobiological and psychological correlates of suicidal attempts and thoughts of death in patients with major depression. Neuropsychobiology 49 (2004) 42-52
20. Fountoulakis K.N., Iacovides A., Gerasimou G., Fotiou F., Ioannidou C., Bascialla F., et al. The relationship of regional cerebral blood flow with subtypes of major depression. Progress in Neuro-psychopharmacology & Biological Psychiatry 28 (2004) 537-546
21. Fountoulakis K.N., Iacovides A., Grammaticos P., St Kaprinis G., and Bech P. Thyroid function in clinical subtypes of major depression: an exploratory study. BMC Psychiatry 4 (2004) 6
22. Fountoulakis K.N., Fotiou F., Iacovides A., and Kaprinis G. Is there a dysfunction in the visual system of depressed patients?. Annual General Psychiatry 4 (2005) 7
23. Fountoulakis K.N., Kaprinis S.G., Iacovides A., Phokas K., and Kaprinis G. Are dexamethasone suppression test nonsuppression and thyroid dysfunction related to a family history of dementia in patients with major depression? An exploratory study. Canadian Journal of Psychiatry 50 (2005) 342-345
24. Frazer A. Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. Journal of Clinical Psychiatry 62 Suppl 12 (2001) 16-23
25. Garattini S., Mennini T., and Samanin R. From fenfluramine racemate to d-fenfluramine: specificity and potency of the effects on the serotoninergic system and food intake. Annals of the New York Academy of Sciences 499 (1987) 156-166
26. Garattini S., Mennini T., and Samanin R. Reduction of food intake by manipulation of central serotonin. British Journal of Psychiatry 155 (1989) 41-51
27. Hartshome M. Single photon emission computed tomography. In: Orrison W., Lewine J., Sanders J., and Hartshorne M. (Eds). Functional Brain Imaging (1995), Mosby-Year Book Inc, St.Louis 213-238
28. Iacovides A., Fountoulakis K.N., Fotiou F., Fokas K., Nimatoudis I., and Kaprinis G. Relation of personality disorders to subtypes of major depression according both to DSM-IV and ICD-10. Canadian Journal of Psychiatry 47 (2002) 196-197
29. Invernissi R., Berettera C., Garattini S., and Samanin R. d- and l-isomers of fenfluramine differ markedly in their interaction with brain serotonin and catecholamines in the rat. European Journal of Pharmacology 120 (1986) 9-15
30. Lacerda A.L., Nicoletti M.A., Brambilla P., Sassi R.B., Mallinger A.G., Frank E., et al. Anatomical MRI study of basal ganglia in major depressive disorder. Psychiatry Research 124 (2003) 129-140
31. Lauterbach E.C., Jackson J.G., Price S.T., Wilson A.N., Kirsh A.D., and Dever G.E. Clinical, motor, and biological correlates of depressive disorders after focal subcortical lesions. Journal of Neuropsychiatry and Clinical Neurosciences 9 (1997) 259-266
32. Lauterbach E.C., Jackson J.G., Wilson A.N., Dever G.E., and Kirsh A.D. Major depression after left posterior globus pallidus lesions. Neuropsychiatry, Neuropsychology, and Behavior Neurology 10 (1997) 9-16
33. Loranger A., Sartorious N., and Andreoli A. The World Health Organisation/Alcohol, Drug Abuse and Mental Health Administration International Pilot Study of personality disorders. Archives of General Psychiatry 51 (1994) 215-224
34. Lowther S., Katona C.L., Crompton M.R., and Horton R.W. 5-HT1D and 5-HT1E/1F binding sites in depressed suicides: increased 5-HT1D binding in globus pallidus but not cortex. Molecular Psychiatry 2 (1997) 314-321
35. Marmor M., and Zrenner E. Standard for clinical electro-oculography. Archives of Ophthalmology (1993) 601-604
36. Mayberg H., and Lewis P. Paralimbic hypoperfusion in unipolar depression. Journal of Nuclear Medicine 35 (1994) 929-934
37. Mendlewicz J., Hubain P., and Koumakis C. Further investigation of the dexamethasone suppression test in affective illness: relationship to clinical diagnosis and therapeutic response. Neuropsychobiology 12 (1984) 23-26
38. Muth E., Huskins J., and Moyer J. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochemical Pharmacology 35 (1986) 4493-4497
39. Nuller J., and Ostroumova M. Resistance to inhibiting effect of dexamethasone in patients with endogenous depression. Acta Psychiatrica Scandinavica 61 (1980) 169-177
40. Ouattrone A., Tedeschi G., Aguglia U., and Scopacasa F. Prolactin secretion in man: a useful tool to evaluate the activity of drugs on central 5-HT neurones. Studies with funfluramine. British Journal of Clinical Pharmacology 16 (1983) 471-475
41. Quattrone A., Schettini G., and DiRenzo G. Effect of midbrain Raphe lesion or 5-7 dihydroxytryptamine treatment on the prolactin releasing action of quipazine and d-fenfluramine in rats. Brain Research 174 (1979) 71-79
42. Regier D., and Burke J. Epidemiology. In: Kaplan H., and Sadock B. (Eds). Comprehensive Textbook of Psychiatry. 5thI ed. vol. I (1989), Williams and Wilkins, Baltimore 308-326
43. Rowland N., and Carlton J. Neurobiology of an anorectic drug: fenfluramine. Progress in Neurobiology 27 (1986) 13-62
44. Segawa K., Azuma H., Sato K., Yasuda T., Arahata K., Otsuki K., et al. Regional cerebral blood flow changes in depression after electroconvulsive therapy. Psychiatry Research (2006)
45. Siever L., and Murphy D. Plasma prolactin changes following fenfluramine in depressed patients compared to controls: an evaluation of central serotonergic responsivity in depression. Life Sciences 34 (1984) 1029-1039
46. Stokes J.M., Pogge D.L., Powell-Lunder J., Ward A.W., Bilginer L., and DeLuca V.A. The Rorschach Ego Impairment Index: prediction of treatment outcome in a child psychiatric population. Journal of Personality Assessment 81 (2003) 11-19
47. The APA Task Force on Laboratory Tests in Psychiatry. The Dexamethasone Suppression Test: An Overview of Its Current Status in Psychiatry. American Journal of Psychiatry 144 (1987) 1253-1262
48. Todd J., Green G., Harrison M., Ikuesan B.A., Self C., Baldacchino A., and Sherwood S. Defining dual diagnosis of mental illness and substance misuse: some methodological issues. Journal of Psychiatric and Mental Health Nursing 11 (2004) 48-54
49. Vataja R., Pohjasvaara T., Leppavuori A., Mantyla R., Aronen H.J., Salonen O., et al. Magnetic resonance imaging correlates of depression after ischemic stroke. Archives of General Psychiatry 58 (2001) 925-931
50. Williams C., and Papakostopoulos D. Electro-oculographic abnormalities in amblyopia. British Journal of Ophthalmology (1995) 218-224
51. Wilson C. Basal ganglia. In: Shepherd G. (Ed). The synaptic organization of the brain (2004), Oxford University Press, Oxford 361-413
52. Wing J., Babor T., and Brugha T. SCAN: schedules for clinical assessment in neuropsychiatry. Archives of General Psychiatry 47 (1990) 589-593
53. Zarifian E. Summary and conclusions. Clinical Neuropharmacology 16 (1993) S51-S53